News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 results as part of the late-breaker session of The Liver Meeting® 2018. The presentation will highlight data from multiple clinical trials of LPCN 1144 in potential non-alcoholic fatty liver disease (“NAFLD”) / non-alcoholic steatohepatitis (“NASH”) patients. The Liver Meeting® 2018, which is the annual meeting of the American Association for the Study of Liver Diseases (“AASLD”), is being held November 9th – 13th in San Francisco, CA.
Oral Testosterone Undecanoate Normalizes Liver
Function Measures and Serum Triglycerides in
Subjects At-Risk for Non-Alcoholic Fatty Liver
Monday, November 12th
Moscone Center North/South Building, Hall C
Monday, November 12: 8:00 am – 5:30 pm;
Presenters Available: 12:30 pm–2:00 pm
LPCN 1144 is an oral androgen targeting androgen signaling pathways. The clinical studies to be presented include a randomized active-controlled clinical study designed to evaluate the efficacy, safety and tolerability of oral androgen therapy in patients having testosterone deficiency and a randomized placebo-controlled clinical study.
“We look forward to sharing the results from our clinical trials with our well-tolerated, safe, oral androgen, LPCN 1144, as part of the late-breaker poster session at The Liver Meeting,” stated Mahesh Patel, Ph.D., Lipocine’s Chairman, President and Chief Executive Officer. “The observed reduction in serum liver enzymes and lipids highlight the promise of LPCN 1144 as a potential therapy for NASH. Our proposed unique mechanism targets the full spectrum of NASH pathogenesis with collateral health benefits associated with treating liver diseases.”